Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines. 

duración terapia de doble antiagregación plaquetaria

Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to DAPT duration. 

Researchers calculated risk ratios of major or life‐threatening bleeding, stroke, and all‐cause mortality. 

Studies using oral anticoagulants and antiplatelet therapy concomitantly, such as those on atrial fibrillation, were excluded. 

It included four randomized controlled trials, 2 propensity‐score matched studies, and 1 observational study, with a total 2498 patients.

1249 received monotherapy, 485 received DAPT for 3 months and 764 received DAPT for 6 months. All these studies used aspirin as monotherapy. 


Read also: CT and Angiography Agreement in Patients from the ISCHEMIA Trial.


The analysis showed that aspirin monotherapy significantly reduced the risk of life-threatening bleeding vs. 3-month DAPT (RR=2.13, p=0.016) and 6-month DAPT (RR=2.54, p=0.007).

There were no differences when comparing 3-month vs 6-month DAPT.

Stroke and mortality rates were similar across groups. 


Read also: Cerebral Protection Devices during TAVR in the Daily Practice.


Clinical guidelines indicating post TAVR DAPT await updating after several studies, and more recently, a meta-analysis with consistent results in favor of monotherapy. 

Conclusion

Aspirin monotherapy after TAVR reduced the risk of bleeding and did not increase stroke or mortality rate vs. 3- and 6-month DAPT. 

JAHA-120-019490free

Original Title: Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis.

Reference: Toshiki Kuno et al. J Am Heart Assoc. 2021;10:e019490.  DOI: 10.1161/JAHA.120.019490.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...